Official websites use. Share sensitive information only on official, secure websites. Chair: Florence Thibaut France. Co-Chairs: John W. Bradford Canada , Paul Cosyns Belgium. Secretary: Peer Briken Germany. The primary aim of these guidelines was to evaluate the role of pharmacological agents in the treatment of adolescents with paraphilic disorders who are also sexual offenders or at-risk of sexual offending. Psychotherapeutic and psychosocial treatments were also reviewed.
Adolescents with paraphilic disorders specifically present a different therapeutic challenge as compared to adults.
In part, the challenge relates to adolescents being in various stages of puberty and development, which may limit the use of certain pharmacological agents due to their potential side effects. In addition, most of the published treatment programmes have used cognitive behavioural interventions, family therapies and psychoeducational interventions. Psychological treatment is predicated in adolescents on the notion that sexually deviant behaviour can be controlled by the offender, and that more adaptive behaviours can be learned.
The main purposes of these guidelines are to improve the quality of care and to aid physicians in their clinical decisions. These guidelines brought together different expert views and involved an extensive literature research. Each treatment recommendation was evaluated and discussed with respect to the strength of evidence for efficacy, safety, tolerability and feasibility.
An algorithm is proposed for the treatment of paraphilic disorders in adolescent sexual offenders or those who are at risk. Keywords: Juvenile sexual offender, paraphilic disorder, psychological treatment, SSRI, antiandrogens. Preliminary note: Most if not all of the literature on this subject concerns adolescents who committed sexual offences according to the laws of their country. Deviant sexual behaviour often starts with the development of deviant sexual fantasies associated with masturbation.
